Ricevi le ultime notizie sulle azioni Exicure con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di XCUR

Ultime notizie per

Exicure

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

IGC Pharma

Pre-Market Outlook

PRGS

QMCO

VERO

XCUR

Mentre i mercati USA si muovono, alcuni titoli sono già sotto i riflettori. Analisi delle azioni da monitorare oggi.

Progress Software, Exicure e altre 3 azioni da tenere d&#39;occhio oggi

Cinque azioni da tenere d&#39;occhio oggi, inclusi Darden Restaurants e FedEx, con risultati trimestrali pronti a sorprendere.

Pre-market: 5 titoli da monitorare oggi C

Earnings

News

Markets

Trading Ideas

CODA

RFIL

VNCE

Coda Octopus, Exicure e altri titoli in movimento nel pre-market: ecco cosa aspettarsi oggi 16 settembre 2024.

Pre-market: 5 titoli da monitorare oggi, 16 settembre 2024

Exicure Inc

Curate

Press Releases

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exicure, Inc. Reports Second Quarter 2025 Financial Results

General

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Exicure, Inc. Reports Third Quarter 2025 Financial Results

Apollomics Inc. - Class A Ordinary Shares

Apollomics

AlphaTON Capital

Boundless Bio

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

iBio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lunai Bioworks

Leap Therapeutics

Moleculin Biotech

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

NextCure

Pluri

Q32 Bio

Rallybio

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Tharimmune

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

Comments

Exicure Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO